Search

Your search keyword '"Magrì G."' showing total 93 results
Start Over Author "Magrì G."
93 results on '"Magrì G."'

1. P412 The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy

Author

Orlando, A., Macaluso, F.S., Fries, W., Privitera, A.C., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, N., Carroccio, A., Genova, S., Calandruccio, G., Vassallo, R., Romano, C., Pellegrino, S., Citrano, M., Accomando, S., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Vinci, E., and Cottone, M.

Published
2017
Full Text
View/download PDF

7. P439 Effectiveness of Ustekinumab on Crohn’s disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

Author

Macaluso, F, primary, Fries, W, additional, Viola, A, additional, Costantino, G, additional, Muscianisi, M, additional, Cappello, M, additional, Guida, L, additional, Giuffrida, E, additional, Magnano, A, additional, Pluchino, D, additional, Ferracane, C, additional, Magrì, G, additional, Di Mitri, R, additional, Mocciaro, F, additional, Privitera, A C, additional, Camilleri, S, additional, Garufi, S, additional, Renna, S, additional, Casà, A, additional, Scrivo, B, additional, Ventimiglia, M, additional, and Orlando, A, additional

Published
2021
Full Text
View/download PDF

9. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Author

Macaluso, F.S., primary, Ventimiglia, M., additional, Fries, W., additional, Viola, A., additional, Cappello, M., additional, Scrivo, B., additional, Magnano, A., additional, Pluchino, D., additional, Camilleri, S., additional, Garufi, S., additional, Di Mitri, R., additional, Mocciaro, F., additional, Magrì, G., additional, Ferracane, C., additional, Citrano, M., additional, Graziano, F., additional, Bertolami, C., additional, Renna, S., additional, Orlando, R., additional, Rizzuto, G., additional, Cottone, M., additional, and Orlando, A., additional

Published
2020
Full Text
View/download PDF

10. Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease

Author

Orlando, A., Macaluso, F., Fries, W., Privitera, A., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, N., Carroccio, A., Genova, S., Bertolami, C., Vassallo, R., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Cottone, M., and Orlando A., Macaluso F.S., Fries W., Privitera A.C., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello N., Carroccio A., Genova S., Bertolami C., Vassallo R., Ventimiglia M., Renna S., Orlando R., Rizzuto G, Cottone M.

Subjects
Sicilian Network, Inflammatory Bowel Disease, SN-IBD, Settore MED/09 - Medicina Interna
Abstract

Background: In the absence of head-to-head trials, there is an unmeet need to better understand the relative effectiveness of different biologics in inflammatory bowel disease (IBD). The Sicilian Network for Inflammatory Bowel Disease (SN-IBD) is a group composed by all Sicilian centres which continuously enter in a web-based software all clinical data of IBD patients treated with biologics. Methods: Data of all incident Crohn’s disease (CD) patients treated with infliximab (IFX) and adalimumab (ADA) from January 2013 to April 2017 were extracted from the cohort of SN-IBD. Patients were divided in biologic-naïve and non-naïve, and the two groups were analysed singularly. We used a one-to-two propensity score matching (1 IFX: 2 ADA) accounting for the main baseline characteristics in naïve patients, and a one-to-one propensity score matching (1 IFX: 1 ADA) in non-naïve. Results: Seven hundred and forty-seven naïve and 188 non-naïve patients were included. After propensity score matching, 453 naïve (IFX: 151; ADA: 302) and 100 non-naïve patients (total treatments: 122; IFX: 61; ADA: 61) were analysed. Among naïve patients, the rates of response/remission at 12 weeks for IFX and ADA were 80.1% and 81.1%,, respectively (adjusted OR 0.97, p = 0.923); over a median follow-up of 11.8 months, the rates of response/remission for IFX and ADA were 70.2% and 66.2%, respectively, without significant differences (adjusted OR 1.14, p = 0.401). Among non-naïve patients, the rates of response/remission at 12 weeks for IFX and ADA were 68.9% and 60.7%, respectively (adjusted OR 1.54, p = 0.320); over a median follow-up of 8.9 months, the rates of response/remission for IFX and ADA were 57.4% and 54.1%, respectively, without significant differences (adjusted OR 1.96, p = 0.297). Cox regression analysis showed no differences in risk of treatment failure between ADA and IFX, neither in naïve (adjusted HR 1.23, p = 0.381) nor in non-naïve patients (adjusted HR 1.23, p = 0.488). At multivariable conditional logistic regression analysis of naïve CD patients, upper GI involvement (OR 0.18, p = 0.038), previous surgery (OR 0.24, p = 0.003), and older age (OR 0.97, p = 0.036) were associated with lower clinical benefit at 12 weeks, while previous surgery was the only independent predictor of treatment failure at the end of follow-up (HR 2.13, p = 0.03). Mixed effect Cox analysis showed that non-naïve patients experiencing more than one previous line of treatment with biologics have a significant higher risk of treatment failure compared with those previously treated with one biologic only (HR 2.57, p = 0.002) Conclusions: In this large, propensity score matched, real-life, multicentre, cohort study of CD patients, there was no significant difference in the effectiveness of ADA and IFX. Both drugs showed a good efficacy.

Published
2018

11. P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results

Author

Viola, A, primary, Fiocco, G, additional, Alibrandi, A, additional, Macaluso, F S, additional, Cappello, M, additional, Privitera, A C, additional, Magrì, G, additional, Garufi, S, additional, Centritto, A, additional, Ventimiglia, M, additional, Giuffrida, E, additional, Ferracane, C, additional, Costantino, G, additional, Renna, S, additional, Orlando, A, additional, and Fries, W, additional

Published
2020
Full Text
View/download PDF

12. P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Author

Macaluso, F S, primary, Ventimiglia, M, additional, Fries, W, additional, Viola, A, additional, Cappello, M, additional, Scrivo, B, additional, Magnano, A, additional, Pluchino, D, additional, Camilleri, S, additional, Garufi, S, additional, Di Mitri, R, additional, Mocciaro, F, additional, Magrì, G, additional, Ferracane, C, additional, Citrano, M, additional, Graziano, F, additional, Bertolami, C, additional, Renna, S, additional, Orlando, R, additional, Rizzuto, G, additional, Cottone, M, additional, and Orlando, A, additional

Published
2020
Full Text
View/download PDF

13. P.07.1 ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Author

Porcari, S., primary, Fidanza, O., additional, Alibrandi, A., additional, Renna, S., additional, Cappello, M., additional, Siringo, S., additional, Privitera, A.C., additional, Inserra, G., additional, Mocciaro, F., additional, Magrì, G., additional, Carroccio, A., additional, Belluardo, N., additional, Bertolami, C., additional, Garufi, S., additional, Ventimiglia, M., additional, Macaluso, F.S., additional, Viola, A., additional, Cottone, M., additional, Orlando, A., additional, and Fries, W., additional

Published
2019
Full Text
View/download PDF

14. The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy

Author

Orlando A., Macaluso F. S., Fries W., Privitera A. C., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello N., Carroccio A., Genova S., Calandruccio G., Vassallo R., Romano C., Pellegrino S., Citrano M., Accomando S., Ventimiglia M., Renna S., Orlando R., Rizzuto G., Vinci E., Cottone M., and Orlando A., Macaluso F.S., Fries W., Privitera A.C., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello N., Carroccio A., Genova S., Calandruccio G., Vassallo R., Romano C., Pellegrino S., Citrano M., Accomando S., Ventimiglia M., Renna S., Orlando R., Rizzuto G., Vinci E., Cottone M.

Subjects
Settore MED/09 - Medicina Interna, biological therapy, inflammatory bowel disease, Sicilian network
Abstract

Background: The monitoring of appropriateness, costs, and clinical outcomes of biological therapy in inflammatory bowel disease (IBD) is a relevant need. We aimed to evaluate all these issues in Sicily through a web based network of all prescribing centers. Methods: From January 2013, all IBD patients starting a biological agent (incident cases) or already on treatment (prevalent cases) were entered in a web based software. Herein we report data of incident cases about the efficacy of biological therapy after twelve weeks and one year of treatment. Results: From January 2013 to October 2016, 1475 patients were included. Incident cases were 1090. Considering that 16% of patients experienced more than one line of therapy, a total of 1351 treatments were reported. Adalimumab was used in 622 Crohn’s disease (CD) patients and in 83 ulcerative colitis (UC)/unclassified colitis patients. Infliximab was prescribed in 275 CD patients (80 biosimilars) and in 279 UC patients (50 biosimilars). Golimumab was used in 32 UC patients, while vedolizumab in 40 CD patients and in 20 UC patients. In patients with CD, after twelve weeks and one year of therapy, the rates of remission with adalimumab were 43.9% and 60.2%, respectively, and the rates of response 40.9% and 25.8%, while the rates of remission with infliximab originator were 46.2% and 50.0%, and the rates of response 40.9% and 32.9% (biosimilars: remission 31.0% and response 51.7% after 12 weeks; remission 45.5% and response 36.4% after one year). In UC, after twelve weeks and one year of therapy, the rates of remission with adalimumab were 43.3% and 57.1%, respectively, and the rates of response 36.7% and 19.0%; the rates of remission with infliximab originator were 41.6% and 48.4%, and the rates of response 35.6% and 32.3% (biosimilars: remission 30.0% and response 63.3% after 12 weeks; remission 20.0% and response 40.0% after one year); the rate of remission after 12 weeks of therapy with Golimumab was 22.2%, and the rate of response was 33.3%. After twelve weeks of therapy with Vedolizumab, 28.6% of CD patients were in remission and 32.0% had a response, while the rates of remission and response in UC patients were 33.3% and 22.0%, respectively. Multivariable logistic regression analysis showed that age >50 years was independently linked to lower rates of remission/response at 12 weeks in CD patients (OR 0.613, p=0.046). Conclusions: In one of the largest series of IBD patients on biological therapy reported to date, CD patients older than 50 years showed a higher rate of non response at 12 weeks of treatment. Efficacy of biosimilars was overall comparable to that reported for infliximab originator.

Published
2017

15. The sicilian network of biological therapy in inflammatory bowel disease: preliminary data from a prospective study on efficacy and safety

Author

Orlando A., Fries W., Privitera A., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello A., Carroccio A., Genova S., Calandruccio G., Vassallo R., Romano C, Magazzù G., Citrano M., Accomando S., Ventimiglia M., Renna S., Orlando R., Rizzuto G., Vinci E., Macaluso F. S., Cottone M., and Orlando A., Fries W., Privitera A., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello A., Carroccio A., Genova S., Calandruccio G., Vassallo R., Romano C, Magazzù G., Citrano M., Accomando S., Ventimiglia M., Renna S., Orlando R., Rizzuto G., Vinci E., Macaluso F.S., Cottone M.

Subjects
Settore MED/09 - Medicina Interna, biological therapy, inflammatory bowel disease, Sicilian network
Abstract

Background and aim: The monitoring of appropriateness and costs of biological therapy in Inflammatory bowel disease (IBD) is a relevant need. We aimed to evaluate appropriateness, efficacy and safety of biological therapy in IBD in Sicily through a web based network of prescribing centers. Material and methods: The Sicilian network for the monitoring of biological therapy in IBD is composed by a super Hub coordinator center and five Hub plus ten Spoke centers. From January 2013 all IBD patients starting a biological agent (incident cases) or already on treatment (prevalent cases) were entered in a web based software. Herein we report data on remission and response after twelve weeks of biological therapy, and side effects until the end of follow-up of incident cases. Results: From January 2013 to June 2016, 1475 patients were included. Complete data were available in 1338 cases (983 with Crohn’s disease [CD], 345 with ulcerative colitis [UC], and 10 with unclassified colitis). Incident cases were 956 (673 CD, 274 UC, and 9 unclassified colitis). Considering that 12% of patients experienced more than one line of therapy, a total of 1098 treatments were reported. Adalimumab was used in 543 CD patients, in 69 UC patients, and in 4 with unclassified colitis. Infliximab was prescribed in 221 CD patients (64 biosimilars), in 226 UC patients (41 biosimilars), and in 5 patients with unclassified colitis. Golimumab was prebscribed in 29 UC patients, and in 1 patient with unclassified colitis. After twelve weeks, the rate of response with Adalimumab was 46% and the rate of remission was 38% in CD, while the rate of response with Infliximab originator was 48% and the rate of remission 42% (biosimilars: 37% and 50%, respectively). In UC the rate of response with Adalimumab was 46% and the rate of remission was 38%, the rate of response with Infliximab was 41% and the rate of remission 45% (biosimilars: 25% and 64%, respectively), while the rate of response with Golimumab was 47% and the rate of remission was 27%. Overall, the rate of side effects was 17% (9.2% with Adalimumab, 20% with Infliximab originator, 15% with biosimilars, and 17% with Golimumab). Conclusions: In one of the largest series of IBD patients on biological therapy reported to date, the rates of remission and response after twelve weeks were comparable to data from literature, and similar between the different biologics. Efficacy and safety of biosimilars were analogous to those reported for infliximab originator.

Published
2017

16. The sicilian network for inflammatory bowel disease (SN-IBD): preliminary data on efficacy of biological therapy

Author

Orlando, A., Macaluso, F., Fries, W., Privitera, A., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, A., Carroccio, A., Genova, S., Bertolami, C., Vassallo, R., Romano, C., Pellegrino, S., Citrano, M., Accomando, S., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Vinci, E., Cottone, M., and Orlando A., Macaluso F.S., Fries W., Privitera A.C., Cappello M., Siringo S., Inserra G., Magnano A., Di Mitri R., Belluardo N., Scarpulla G., Magrì G., Trovatello A., Carroccio A., Genova S., Bertolami C., Vassallo R., Romano C., Pellegrino S., Citrano M., Accomando S., Ventimiglia M., Renna S., Orlando R., Rizzuto G., Vinci E., Cottone M.

Subjects
Settore MED/09 - Medicina Interna, Sicilian network, inflammatory bowel disease, SN-IBD
Abstract

Introduction: The monitoring of appropriateness, costs, and clinical outcomes of biological therapy in inflammatory bowel disease (IBD) is a relevant need. Aims & Methods: We aimed to evaluate all these issues in Sicily through a webbased network of all prescribing centers. The Sicilian Network for Inflammatory Bowel Disease (SN-IBD) is composed by a super Hub coordinator centre and five Hub plus ten Spoke centres. From January 2013, all IBD patients starting a biological agent (incident cases) or already on treatment (prevalent cases) were entered in a web based software. Herein we report data of incident cases about the efficacy of biological therapy after twelve weeks and one year of treatment. As clinical end-point, we set remission (corresponding to a Mayo Partial Score 52 for UC, and to a Harvey-Bradshaw Index 55 for CD), and response (reduction of Harvey-Bradshaw Index

Published
2017

17. OC.02.4 THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD): A COMPARISON OF THE EFFICACY OF CURRENT BIOLOGICS IN CROHN'S DISEASE

Author

Orlando, A., primary, Macaluso, F.S., additional, Fries, W., additional, Privitera, A.C., additional, Cappello, M., additional, Siringo, S., additional, Inserra, G., additional, Magnano, A., additional, Di Mitri, R., additional, Belluardo, N., additional, Scarpulla, G., additional, Magrì, G., additional, Trovatello, A., additional, Carroccio, A., additional, Genova, S., additional, Bertolami, C., additional, Vassallo, R., additional, Romano, C., additional, Pellegrino, S., additional, Citrano, M., additional, Accomando, S., additional, Ventimiglia, M., additional, Renna, S., additional, Orlando, R., additional, Rizzuto, G., additional, Ferracane, C., additional, and Cottone, M., additional

Published
2018
Full Text
View/download PDF

19. Intracellular Mechanisms in GH Control

Author

Schettini, G., Florio, T., Meucci, O., Landolfi, E., Grimaldi, M., Magri, G., Merola, B., Lombardi, G., Müller, Eugenio E., editor, MacLeod, Robert M., editor, Wass, John A. H., editor, and Scanlon, Maurice F., editor

Published
1989
Full Text
View/download PDF

23. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety

Author

Orlando, A., primary, Fries, W., additional, Privitera, A., additional, Cappello, M., additional, Siringo, S., additional, Inserra, G., additional, Magnano, A., additional, Di Mitri, R., additional, Belluardo, N., additional, Scarpulla, G., additional, Magrì, G., additional, Trovatello, A., additional, Carroccio, A., additional, Genova, S., additional, Calandruccio, G., additional, Vassallo, R., additional, Romano, C., additional, Magazzù, G., additional, Citrano, M., additional, Accomando, S., additional, Ventimiglia, M., additional, Renna, S., additional, Orlando, R., additional, Rizzuto, G., additional, Vinci, E., additional, Macaluso, F.S., additional, and Cottone, M., additional

Published
2017
Full Text
View/download PDF

24. Screening for colorectal cancer in Italy: 2011-2012 survey

Author

Zorzi, Manuel, Da Re, Filippo, Mantellini, Paola, Naldoni, Carlo, De Bianchi, Priscilla Sassoli, Senore, Carlo, Turrin, Anna, Visioli, Carmen Beatriz, Zappa, Marco, Crotta, S., Senore, C., Polizzi, S., Sartori, M., Alibrandi, M. P., Germinetti, F., Bestagini, P., Orione, L., Miroglio, T., Faragli, G., Cereda, D., Coppola, L., Zerbi, L., Gramegna, M., Tessandri, L., Imbrogno, P., Rocca, G., Pesenti, B., Schivardi, M., Crisetig, M., Grassi, E., Speziani, F., Gola, G., Gotti, S., Dal Soldà, M., Boldori, L., Moretti, G., Ilardo, A., Ieni, A, Belloni, A., Rossetti, E., Marazza, G., Anghinoni, E., Silvestri, A., Tidone, E., Frammartino, B., Leonardo, N., Deandrea, S., Ceresa, P., Beghi, G., Lucchini, R., Acerbi, L., Lo Buono, F., Cavalieri D'Oro, L., Magenes, G., Camana, L., Cioccarelli, A. M., Fanetti, A. C., Cecconami, L., Bardelli, R., Violini, M., Sambo, F., Domenighini, S., Pieracci, G., Pertile, R., Piffer, S., Fedato, C., Franzo, A., Fabro, J., Gobbato, M., Zanier, L., Bonelli, L., Orlando, M., Vaccari, D., Franxo, A., Scotto, M., Valle, I., Ferrari Bravo, M., Sticchi, C., Maddalo, F., Pensa, F., Naldoni, C., Sassoli De Bianchi, P., Landi, P., Borciani, E., Fornari, F., Gatti, G., Zurlini, C., Zatelli, M., Maradini, F., Paterlini, L., Campari, C., Sassatelli, R., Corradini, R., Goldoni, C., Pasquini, A., Manfredi, M., Baldazzi, P., Nannini, R., Caprara, L., Carpanelli, M. C., Zoli, G., Matarese, V., Triossi, O., Serafini, M., Vitali, B., Falcini, F., Colamartini, A., Giuliani, O., Vattiato, R., Palazzi, M., Imolesi, C., Pazzi, P., Canuti, D., Casale, C., Giovanardi, M., Monticelli, G., Nicolai, C., Vivani, P., Giorgi, D., Finucci, G., Rapanà, M., Epifani, C., Abdelghani, L., Allegrini, G., Maffei, C., Turillazzi, R., Mirri, F., Ceccatelli, P., Rosati, R., Piacentini, P., Visioli, C. B., Falini, P., Amico, P., Ciabattoni, C., Giaimo, M., Prandini, S., Vinti, G., Di Marco, A., Malaspina, M., Corvetti, R., Di Furia, L., Barca, A., Baiocchi, D., Quadrino, F., Di Giacomo, M., Lattanzio, F. M., Minna, M., Di Credico, A., Pizzuti, R., Sigillito, A., Montesi, M. P., Landro, T., Giorno, A., Santino, M., Magrì, G., Ferrara, G., and Masala, R.

Subjects
Flexible sigmoidoscopy, National survey, Faecal immunochemical test, Italy, Colorectal cancer, Screening, Epidemiology, Public Health, Environmental and Occupational Health, Environmental and Occupational Health, Public Health
Published
2015

43. Screening for colorectal cancer in Italy: 2011-2012 survey

Author

Zorzi, M., Da Re, F., Mantellini, P., Naldoni, C., Bianchi, P. S., Senore, C., Turrin, A., Visioli, C. B., Zappa, M., Crotta, S., Polizzi, S., Sartori, M., Alibrandi, M. P., Germinetti, F., Bestagini, P., Orione, L., Miroglio, T., Faragli, G., Cereda, D., Coppola, L., Zerbi, L., Gramegna, M., Tessandri, L., Imbrogno, P., Rocca, G., Pesenti, B., Schivardi, M., Crisetig, M., Grassi, E., Speziani, F., Gola, G., Gotti, S., Dal Soldà, M., Boldori, L., Moretti, G., Ilardo, A., Belloni, A., Rossetti, E., Marazza, G., Anghinoni, E., Silvestri, A., Tidone, E., Frammartino, B., Leonardo, N., Deandrea, S., Ceresa, P., Beghi, G., Lucchini, R., Acerbi, L., Lo Buono, F., Cavalieri D Oro, L., Magenes, G., Camana, L., Cioccarelli, A. M., Fanetti, A. C., Cecconami, L., Bardelli, R., Violini, M., Sambo, F., Domenighini, S., Pieracci, G., Pertile, R., Piffer, S., Fedato, C., Franzo, A., Fabro, J., Gobbato, M., Zanier, L., Bonelli, L., Orlando, M., Vaccari, D., Franxo, A., Scotto, M., Valle, I., Ferrari Bravo, M., Sticchi, C., Maddalo, F., Pensa, F., Sassoli Bianchi, P., Landi, P., Borciani, E., Fornari, F., Gatti, G., Zurlini, C., Zatelli, M., Maradini, F., Paterlini, L., Cinzia Campari, Sassatelli, R., Corradini, R., Goldoni, C., Pasquini, A., Manfredi, M., Baldazzi, P., Nannini, R., Caprara, L., Carpanelli, M. C., Zoli, G., Matarese, V., Triossi, O., Serafini, M., Vitali, B., Falcini, F., Colamartini, A., Giuliani, O., Vattiato, R., Palazzi, M., Imolesi, C., Pazzi, P., Canuti, D., Casale, C., Giovanardi, M., Monticelli, G., Nicolai, C., Vivani, P., Giorgi, D., Finucci, G., Rapanà, M., Epifani, C., Abdelghani, L., Allegrini, G., Maffei, C., Turillazzi, R., Mirri, F., Ceccatelli, P., Rosati, R., Piacentini, P., Falini, P., Amico, P., Ciabattoni, C., Giaimo, M., Prandini, S., Vinti, G., Di Marco, A., Malaspina, M., Corvetti, R., Di Furia, L., Barca, A., Baiocchi, D., Quadrino, F., Di Giacomo, M., Lattanzio, F. M., Minna, M., Di Credico, A., Pizzuti, R., Sigillito, A., Montesi, M. P., Landro, T., Giorno, A., Santino, M., Magrì, G., Ferrara, G., and Masala, R.

44. Screening for colorectal cancer in Italy: 2011-2012 survey

Author

Zorzi, M., Da Re, F., Mantellini, P., Naldoni, C., Bianchi, P. S., Senore, C., Turrin, A., Visioli, C. B., Zappa, M., Crotta, S., Polizzi, S., Sartori, M., Alibrandi, M. P., Germinetti, F., Bestagini, P., Orione, L., Miroglio, T., Faragli, G., danilo Cereda, Coppola, L., Zerbi, L., Gramegna, M., Tessandri, L., Imbrogno, P., Rocca, G., Pesenti, B., Schivardi, M., Crisetig, M., Grassi, E., Speziani, F., Gola, G., Gotti, S., Dal Soldà, M., Boldori, L., Moretti, G., Ilardo, A., Belloni, A., Rossetti, E., Marazza, G., Anghinoni, E., Silvestri, A., Tidone, E., Frammartino, B., Leonardo, N., Deandrea, S., Ceresa, P., Beghi, G., Lucchini, R., Acerbi, L., Lo Buono, F., Cavalieri D Oro, L., Magenes, G., Camana, L., Cioccarelli, A. M., Fanetti, A. C., Cecconami, L., Bardelli, R., Violini, M., Sambo, F., Domenighini, S., Pieracci, G., Pertile, R., Piffer, S., Fedato, C., Franzo, A., Fabro, J., Gobbato, M., Zanier, L., Bonelli, L., Orlando, M., Vaccari, D., Franxo, A., Scotto, M., Valle, I., Ferrari Bravo, M., Sticchi, C., Maddalo, F., Pensa, F., Sassoli Bianchi, P., Landi, P., Borciani, E., Fornari, F., Gatti, G., Zurlini, C., Zatelli, M., Maradini, F., Paterlini, L., Campari, C., Sassatelli, R., Corradini, R., Goldoni, C., Pasquini, A., Manfredi, M., Baldazzi, P., Nannini, R., Caprara, L., Carpanelli, M. C., Zoli, G., Matarese, V., Triossi, O., Serafini, M., Vitali, B., Falcini, F., Colamartini, A., Giuliani, O., Vattiato, R., Palazzi, M., Imolesi, C., Pazzi, P., Canuti, D., Casale, C., Giovanardi, M., Monticelli, G., Nicolai, C., Vivani, P., Giorgi, D., Finucci, G., Rapanà, M., Epifani, C., Abdelghani, L., Allegrini, G., Maffei, C., Turillazzi, R., Mirri, F., Ceccatelli, P., Rosati, R., Piacentini, P., Falini, P., Amico, P., Ciabattoni, C., Giaimo, M., Prandini, S., Vinti, G., Di Marco, A., Malaspina, M., Corvetti, R., Di Furia, L., Barca, A., Baiocchi, D., Quadrino, F., Di Giacomo, M., Lattanzio, F. M., Minna, M., Di Credico, A., Pizzuti, R., Sigillito, A., Montesi, M. P., Landro, T., Giorno, A., Santino, M., Magrì, G., Ferrara, G., and Masala, R.

Catalog

Books, media, physical & digital resources
See catalog results